Sema Ciftci Dogansen1, Gulsah Yenidunya Yalin2, Seher Tanrikulu2, Sakin Tekin2, Nihan Nizam2, Bilge Bilgic3, Serra Sencer4, Sema Yarman2. 1. Division of Endocrinology and Metabolism, Capa, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34090, Istanbul, Turkey. sdogansen@gmail.com. 2. Division of Endocrinology and Metabolism, Capa, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34090, Istanbul, Turkey. 3. Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 4. Department of Neuroradiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Abstract
PURPOSE: To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing's disease (CD). METHODS: Somatotroph adenomas (n = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation patterns and response to treatment. RESULTS: Somatotroph adenomas were mostly hypointense (53%), prolactinomas were dominantly hyperintense (55%), and corticotroph adenomas were generally hyperintense (45%). Hyperintense somatotroph adenomas were larger in size with sparsely granulated pattern and tumor shrinkage rate was lower after somatostatin analogues (SSA) (p = 0.007, p = 0.035, p = 0.029, respectively). T2 hypointensity was related with higher baseline IGF-1% ULN (upper limit of normal) levels and a better response to SSA treatment (p = 0.02, p = 0.045, respectively). In female prolactinomas, hyperintensity was correlated with a smaller adenoma diameter (p = 0.001). Hypointense female prolactinomas were related to younger age at diagnosis, higher baseline PRL levels and dopamine agonist (DA) resistance (p = 0.009, p = 0.022, p < 0.001, respectively). Hyperintense corticotroph adenomas were related to larger adenoma size and sparsely granulated pattern (p = 0.04, p = 0.017, respectively). There was no significant difference in the recurrence with T2WSI in CD. CONCLUSION: Baseline hypointense somatotroph adenomas show a better response to SSA, whereas hypointensity was related to DA resistance in female prolactinomas.
PURPOSE: To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing's disease (CD). METHODS:Somatotroph adenomas (n = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation patterns and response to treatment. RESULTS:Somatotroph adenomas were mostly hypointense (53%), prolactinomas were dominantly hyperintense (55%), and corticotroph adenomas were generally hyperintense (45%). Hyperintense somatotroph adenomas were larger in size with sparsely granulated pattern and tumor shrinkage rate was lower after somatostatin analogues (SSA) (p = 0.007, p = 0.035, p = 0.029, respectively). T2 hypointensity was related with higher baseline IGF-1% ULN (upper limit of normal) levels and a better response to SSA treatment (p = 0.02, p = 0.045, respectively). In female prolactinomas, hyperintensity was correlated with a smaller adenoma diameter (p = 0.001). Hypointense female prolactinomas were related to younger age at diagnosis, higher baseline PRL levels and dopamine agonist (DA) resistance (p = 0.009, p = 0.022, p < 0.001, respectively). Hyperintense corticotroph adenomas were related to larger adenoma size and sparsely granulated pattern (p = 0.04, p = 0.017, respectively). There was no significant difference in the recurrence with T2WSI in CD. CONCLUSION: Baseline hypointense somatotroph adenomas show a better response to SSA, whereas hypointensity was related to DA resistance in female prolactinomas.
Authors: Luis V Syro; Fabio Rotondo; Michael D Cusimano; Antonio Di Ieva; Eva Horvath; Lina M Restrepo; Min Wong; Donald W Killinger; Harley Smyth; Kalman Kovacs Journal: Pituitary Date: 2015-04 Impact factor: 4.107
Authors: Iulia Potorac; Patrick Petrossians; Adrian F Daly; Orsalia Alexopoulou; Sophie Borot; Mona Sahnoun-Fathallah; Frederic Castinetti; France Devuyst; Marie-Lise Jaffrain-Rea; Claire Briet; Florina Luca; Marion Lapoirie; Flavius Zoicas; Isabelle Simoneau; Alpha M Diallo; Ammar Muhammad; Fahrettin Kelestimur; Elena Nazzari; Rogelio Garcia Centeno; Susan M Webb; Marie-Laure Nunes; Vaclav Hana; Véronique Pascal-Vigneron; Irena Ilovayskaya; Farida Nasybullina; Samia Achir; Diego Ferone; Sebastian J C M M Neggers; Brigitte Delemer; Jean-Michel Petit; Christof Schöfl; Gerald Raverot; Bernard Goichot; Patrice Rodien; Bernard Corvilain; Thierry Brue; Franck Schillo; Luaba Tshibanda; Dominique Maiter; Jean-François Bonneville; Albert Beckers Journal: Endocr Relat Cancer Date: 2016-09-20 Impact factor: 5.678
Authors: Iulia Potorac; Patrick Petrossians; Adrian F Daly; Franck Schillo; Claude Ben Slama; Sonia Nagi; Mouna Sahnoun; Thierry Brue; Nadine Girard; Philippe Chanson; Ghaidaa Nasser; Philippe Caron; Fabrice Bonneville; Gérald Raverot; Véronique Lapras; François Cotton; Brigitte Delemer; Brigitte Higel; Anne Boulin; Stéphan Gaillard; Florina Luca; Bernard Goichot; Jean-Louis Dietemann; Albert Beckers; Jean-François Bonneville Journal: Endocr Relat Cancer Date: 2015-01-02 Impact factor: 5.678
Authors: John R Lindsay; Edward H Oldfield; Constantine A Stratakis; Lynnette K Nieman Journal: J Clin Endocrinol Metab Date: 2011-04-20 Impact factor: 5.958
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini Journal: Pituitary Date: 2020-10-19 Impact factor: 4.107
Authors: Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed Journal: Rev Endocr Metab Disord Date: 2020-09-10 Impact factor: 6.514